Announcement • May 28
Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on Jul 10, 2026 Daito Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on Jul 10, 2026 Upcoming Dividend • May 21
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 28 May 2026. Payment date: 05 August 2026. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.7%). Major Estimate Revision • Apr 17
Consensus EPS estimates increase by 19%, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from JP¥51.8b to JP¥51.0b. EPS estimate rose from JP¥72.80 to JP¥86.30. Net income forecast to shrink 12% next year vs 8.4% growth forecast for Pharmaceuticals industry in Japan . Consensus price target up from JP¥1,400 to JP¥1,500. Share price fell 3.3% to JP¥1,356 over the past week. Reported Earnings • Apr 11
Third quarter 2026 earnings released: EPS: JP¥35.41 (vs JP¥10.15 in 3Q 2025) Third quarter 2026 results: EPS: JP¥35.41 (up from JP¥10.15 in 3Q 2025). Revenue: JP¥11.6b (down 3.6% from 3Q 2025). Net income: JP¥1.03b (up 235% from 3Q 2025). Profit margin: 8.9% (up from 2.6% in 3Q 2025). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Apr 03
Daito Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Apr 10, 2026 Daito Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Apr 10, 2026 Declared Dividend • Feb 03
First half dividend of JP¥20.00 announced Shareholders will receive a dividend of JP¥20.00. Ex-date: 28th May 2026 Payment date: 5th August 2026 Dividend yield will be 3.0%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Price Target Changed • Jan 20
Price target increased by 17% to JP¥1,400 Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of JP¥1,344. Stock is up 31% over the past year. The company is forecast to post earnings per share of JP¥72.80 for next year compared to JP¥62.72 last year. Reported Earnings • Jan 15
Second quarter 2026 earnings released: EPS: JP¥18.09 (vs JP¥9.48 in 2Q 2025) Second quarter 2026 results: EPS: JP¥18.09 (up from JP¥9.48 in 2Q 2025). Revenue: JP¥12.1b (up 1.9% from 2Q 2025). Net income: JP¥537.0m (up 85% from 2Q 2025). Profit margin: 4.4% (up from 2.4% in 2Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Upcoming Dividend • Nov 20
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 27 November 2025. Payment date: 03 February 2026. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.5%). Announcement • Nov 01
Daito Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Jan 14, 2026 Daito Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Jan 14, 2026 Reported Earnings • Oct 11
First quarter 2026 earnings released: EPS: JP¥23.21 (vs JP¥14.84 in 1Q 2025) First quarter 2026 results: EPS: JP¥23.21 (up from JP¥14.84 in 1Q 2025). Revenue: JP¥13.0b (up 5.8% from 1Q 2025). Net income: JP¥696.0m (up 53% from 1Q 2025). Profit margin: 5.3% (up from 3.7% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Declared Dividend • Sep 08
Final dividend of JP¥20.00 announced Shareholders will receive a dividend of JP¥20.00. Ex-date: 27th November 2025 Payment date: 3rd February 2026 Dividend yield will be 4.4%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by earnings (56% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 61% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Sep 02
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: JP¥125. Revenue: JP¥50.6b (up 8.0% from FY 2024). Net income: JP¥1.91b (down 42% from FY 2024). Profit margin: 3.8% (down from 7.0% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Announcement • Aug 27
Daito Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Oct 10, 2025 Daito Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Oct 10, 2025 Reported Earnings • Jul 14
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: JP¥125. Revenue: JP¥50.6b (up 8.0% from FY 2024). Net income: JP¥1.91b (down 42% from FY 2024). Profit margin: 3.8% (down from 7.0% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Japan. Announcement • Jul 11
Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 28, 2025 Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 28, 2025. Announcement • May 27
Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on Jul 11, 2025 Daito Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on Jul 11, 2025 Upcoming Dividend • May 22
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 06 August 2025. Payout ratio is a comfortable 46% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Japanese dividend payers (4.0%). Higher than average of industry peers (2.7%). Major Estimate Revision • Apr 21
Consensus EPS estimates fall by 29% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from JP¥140 to JP¥100.00. Revenue forecast unchanged from JP¥49.0b at last update. Net income forecast to shrink 10% next year vs 2.1% decline forecast for Pharmaceuticals industry in Japan. Consensus price target down from JP¥2,160 to JP¥1,960. Share price fell 5.0% to JP¥2,050 over the past week. New Risk • Apr 15
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.4% Last year net profit margin: 7.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.4% net profit margin). Reported Earnings • Apr 15
Third quarter 2025 earnings released: EPS: JP¥20.30 (vs JP¥50.14 in 3Q 2024) Third quarter 2025 results: EPS: JP¥20.30 (down from JP¥50.14 in 3Q 2024). Revenue: JP¥12.0b (up 14% from 3Q 2024). Net income: JP¥309.0m (down 61% from 3Q 2024). Profit margin: 2.6% (down from 7.5% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Apr 14
Daito Pharmaceutical Co.,Ltd. Revises Consolidated Financial Earnings Guidance for the Year Ending May 31, 2025 Daito Pharmaceutical Co.,Ltd. revised consolidated financial earnings guidance for the year ending May 31, 2025. For the year, the company expects Net sales of ¥49,000 million, Operating profit of ¥2,450 million, Profit attributable to owners of parent of ¥1,500 million and Earnings per share of ¥98.24. Announcement • Mar 14
Daito Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Apr 14, 2025 Daito Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Apr 14, 2025 Declared Dividend • Feb 04
First half dividend of JP¥35.00 announced Shareholders will receive a dividend of JP¥35.00. Ex-date: 29th May 2025 Payment date: 6th August 2025 Dividend yield will be 3.4%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Major Estimate Revision • Jan 17
Consensus EPS estimates fall by 21% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from JP¥49.5b to JP¥49.0b. EPS estimate also fell from JP¥177 per share to JP¥140 per share. Net income forecast to shrink 9.4% next year vs 1.8% growth forecast for Pharmaceuticals industry in Japan . Consensus price target down from JP¥2,780 to JP¥2,160. Share price rose 2.1% to JP¥2,037 over the past week. Price Target Changed • Jan 15
Price target decreased by 26% to JP¥2,160 Down from JP¥2,905, the current price target is provided by 1 analyst. New target price is 5.4% above last closing price of JP¥2,050. Stock is up 8.6% over the past year. The company is forecast to post earnings per share of JP¥140 for next year compared to JP¥210 last year. Reported Earnings • Jan 12
First half 2025 earnings released: EPS: JP¥59.37 (vs JP¥98.21 in 1H 2024) First half 2025 results: EPS: JP¥59.37 (down from JP¥98.21 in 1H 2024). Revenue: JP¥24.6b (up 2.0% from 1H 2024). Net income: JP¥908.0m (down 42% from 1H 2024). Profit margin: 3.7% (down from 6.4% in 1H 2024). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Jan 11
Daito Pharmaceutical Co.,Ltd. Announces Second Quarter Cash Dividend for the Year Ending May 31, 2025, Payable on February 3, 2025 and Provides Fiscal Year Ending Cash Dividend Guidance for the Year Ending May 31, 2025 Daito Pharmaceutical Co.,Ltd. announced second quarter cash dividend of ¥35.00 for the year ending May 31, 2025. Scheduled date to commence dividend payments: February 3, 2025.
For the fiscal year, the company expects cash dividend Of ¥35.00. Announcement • Nov 27
Daito Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Jan 10, 2025 Daito Pharmaceutical Co.,Ltd. announced that they will report Q2, 2025 results on Jan 10, 2025 Upcoming Dividend • Nov 21
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 28 November 2024. Payment date: 03 February 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.4%). Reported Earnings • Oct 16
First quarter 2025 earnings released: EPS: JP¥40.41 (vs JP¥47.55 in 1Q 2024) First quarter 2025 results: EPS: JP¥40.41 (down from JP¥47.55 in 1Q 2024). Revenue: JP¥12.7b (up 4.1% from 1Q 2024). Net income: JP¥618.0m (down 9.5% from 1Q 2024). Profit margin: 4.9% (down from 5.6% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Board Change • Sep 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Chairman of the Board Yasunobu Otsuga was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 05
Full year 2024 earnings released: EPS: JP¥210 (vs JP¥228 in FY 2023) Full year 2024 results: EPS: JP¥210 (down from JP¥228 in FY 2023). Revenue: JP¥46.9b (up 4.0% from FY 2023). Net income: JP¥3.30b (down 8.5% from FY 2023). Profit margin: 7.0% (down from 8.0% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 11% per year. Reported Earnings • Jul 16
Full year 2024 earnings released: EPS: JP¥210 (vs JP¥228 in FY 2023) Full year 2024 results: EPS: JP¥210 (down from JP¥228 in FY 2023). Revenue: JP¥46.9b (up 4.0% from FY 2023). Net income: JP¥3.30b (down 8.5% from FY 2023). Profit margin: 7.0% (down from 8.0% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • Jul 13
Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2024 Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2024. New Risk • Jun 14
New major risk - Revenue and earnings growth Earnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows. Upcoming Dividend • May 23
Upcoming dividend of JP¥30.00 per share Eligible shareholders must have bought the stock before 30 May 2024. Payment date: 07 August 2024. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 2.6%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (2.5%). Reported Earnings • Apr 14
Third quarter 2024 earnings released: EPS: JP¥50.14 (vs JP¥56.83 in 3Q 2023) Third quarter 2024 results: EPS: JP¥50.14 (down from JP¥56.83 in 3Q 2023). Revenue: JP¥10.6b (down 5.8% from 3Q 2023). Net income: JP¥787.0m (down 12% from 3Q 2023). Profit margin: 7.5% (down from 8.0% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 12% per year. Announcement • Apr 12
Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million. Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces a share repurchase program. Under the program, the company will repurchase up to 350,000 shares, representing 2.23% of its issued share capital (excluding treasury stock), for a total purchase price of ¥1,000 million. The purpose of the program is to improve capital efficiency and enhance shareholder returns. The plan will expire on June 28, 2024. As of March 31, 2024, the company has 15,690,407 issued shares (excluding treasury stock) and 8,033 treasury shares. Price Target Changed • Mar 09
Price target increased by 8.6% to JP¥3,155 Up from JP¥2,905, the current price target is an average from 2 analysts. New target price is 44% above last closing price of JP¥2,193. Stock is down 5.3% over the past year. The company is forecast to post earnings per share of JP¥219 for next year compared to JP¥228 last year. Announcement • Feb 02
Daito Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Apr 12, 2024 Daito Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Apr 12, 2024 Reported Earnings • Jan 14
Second quarter 2024 earnings released: EPS: JP¥50.40 (vs JP¥51.58 in 2Q 2023) Second quarter 2024 results: EPS: JP¥50.40. Revenue: JP¥11.9b (up 5.4% from 2Q 2023). Net income: JP¥869.0m (up 6.5% from 2Q 2023). Profit margin: 7.3% (up from 7.2% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Announcement • Jan 13
Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 160,000 shares, representing 1.01% for ¥303.36 million. Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces a share repurchase program. Under the program, the company will repurchase up to 160,000 shares, representing 1.01% of its issued share capital (excluding treasury stock), for a total purchase price of ¥303.36 million. The shares will be repurchased at a price of ¥1,896 per share. The purpose of the program is to improve capital efficiency, implement flexible capital policies in response to changes in the business environment, and enhance shareholder returns. As of December 31, 2023, the company has 15,850,770 issued shares (excluding treasury stock) and 7,670 treasury shares. Announcement • Nov 29
Daito Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Jan 12, 2024 Daito Pharmaceutical Co.,Ltd. announced that they will report Q2, 2024 results on Jan 12, 2024 Upcoming Dividend • Nov 22
Upcoming dividend of JP¥30.00 per share at 2.8% yield Eligible shareholders must have bought the stock before 29 November 2023. Payment date: 01 February 2024. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (2.4%). Reported Earnings • Oct 13
First quarter 2024 earnings released: EPS: JP¥47.54 (vs JP¥59.74 in 1Q 2023) First quarter 2024 results: EPS: JP¥47.54 (down from JP¥59.74 in 1Q 2023). Revenue: JP¥12.2b (up 1.1% from 1Q 2023). Net income: JP¥683.0m (down 28% from 1Q 2023). Profit margin: 5.6% (down from 7.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Reported Earnings • Sep 05
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: JP¥250 (down from JP¥305 in FY 2022). Revenue: JP¥45.1b (up 3.8% from FY 2022). Net income: JP¥3.60b (down 23% from FY 2022). Profit margin: 8.0% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 9% per year. Announcement • Sep 03
Daito Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Oct 12, 2023 Daito Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Oct 12, 2023 Reported Earnings • Jul 16
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: JP¥250 (down from JP¥335 in FY 2022). Revenue: JP¥45.1b (up 3.8% from FY 2022). Net income: JP¥3.60b (down 23% from FY 2022). Profit margin: 8.0% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 14%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 11% per year. Announcement • Jul 16
Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023 Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023. Announcement • May 28
Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Jul 14, 2023 Daito Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2023 results on Jul 14, 2023 Upcoming Dividend • May 23
Upcoming dividend of JP¥30.00 per share at 2.4% yield Eligible shareholders must have bought the stock before 30 May 2023. Payment date: 03 August 2023. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.5%). In line with average of industry peers (2.3%). Reported Earnings • Apr 15
Third quarter 2023 earnings released: EPS: JP¥62.51 (vs JP¥85.94 in 3Q 2022) Third quarter 2023 results: EPS: JP¥62.51 (down from JP¥85.94 in 3Q 2022). Revenue: JP¥11.2b (flat on 3Q 2022). Net income: JP¥898.0m (down 25% from 3Q 2022). Profit margin: 8.0% (down from 11% in 3Q 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 10% per year. Reported Earnings • Jan 14
Second quarter 2023 earnings released: EPS: JP¥56.74 (vs JP¥69.11 in 2Q 2022) Second quarter 2023 results: EPS: JP¥56.74 (down from JP¥69.11 in 2Q 2022). Revenue: JP¥11.3b (up 5.7% from 2Q 2022). Net income: JP¥816.0m (down 14% from 2Q 2022). Profit margin: 7.2% (down from 8.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Buying Opportunity • Dec 19
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.8%. The fair value is estimated to be JP¥3,138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings is forecast to grow by 0.7% in the next 2 years. Announcement • Nov 23
Daito Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Jan 13, 2023 Daito Pharmaceutical Co.,Ltd. announced that they will report Q2, 2023 results on Jan 13, 2023 Upcoming Dividend • Nov 22
Upcoming dividend of JP¥30.00 per share Eligible shareholders must have bought the stock before 29 November 2022. Payment date: 01 February 2023. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.7%). In line with average of industry peers (2.2%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. 2 independent directors (4 non-independent directors). Senior MD & Director Junichi Kikuta was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 15
First quarter 2023 earnings released: EPS: JP¥65.71 (vs JP¥133 in 1Q 2022) First quarter 2023 results: EPS: JP¥65.71 (down from JP¥133 in 1Q 2022). Revenue: JP¥12.0b (up 2.5% from 1Q 2022). Net income: JP¥946.0m (down 48% from 1Q 2022). Profit margin: 7.9% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Aug 31
Daito Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Oct 13, 2022 Daito Pharmaceutical Co.,Ltd. announced that they will report Q1, 2023 results on Oct 13, 2022 Major Estimate Revision • Jul 22
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 EPS estimate fell from JP¥333 to JP¥254. Revenue forecast unchanged from JP¥45.0b at last update. Net income forecast to shrink 22% next year vs 7.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target of JP¥4,200 unchanged from last update. Share price rose 4.1% to JP¥2,742 over the past week. Major Estimate Revision • Jul 21
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 EPS estimate fell from JP¥333 to JP¥271. Revenue forecast unchanged from JP¥45.0b at last update. Net income forecast to shrink 16% next year vs 7.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target down from JP¥4,800 to JP¥4,200. Share price fell 4.9% to JP¥2,694 over the past week. Reported Earnings • Jul 17
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: JP¥335 (up from JP¥311 in FY 2021). Revenue: JP¥43.5b (down 11% from FY 2021). Net income: JP¥4.67b (up 9.9% from FY 2021). Profit margin: 11% (up from 8.7% in FY 2021). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 3.5%, compared to a 6.0% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jul 16
Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022 Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022. Buying Opportunity • Jul 15
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 4.2%. The fair value is estimated to be JP¥3,356, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has grown by 6.3%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 5.8% per annum over the same time period. Buying Opportunity • Jun 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 4.2%. The fair value is estimated to be JP¥3,373, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has grown by 6.3%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 5.8% per annum over the same time period. Announcement • May 25
Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on Jul 14, 2022 Daito Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2022 results on Jul 14, 2022 Buying Opportunity • May 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.5%. The fair value is estimated to be JP¥3,354, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has grown by 6.3%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 5.8% per annum over the same time period. Upcoming Dividend • May 23
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 30 May 2022. Payment date: 04 August 2022. Payout ratio is a comfortable 15% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.5%). Price Target Changed • Apr 27
Price target decreased to JP¥4,800 Down from JP¥5,600, the current price target is provided by 1 analyst. New target price is 87% above last closing price of JP¥2,563. Stock is down 27% over the past year. The company is forecast to post earnings per share of JP¥311 for next year compared to JP¥311 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. 2 independent directors (4 non-independent directors). Senior MD & Director Junichi Kikuta was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 15
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: JP¥85.92 (down from JP¥93.05 in 3Q 2021). Revenue: JP¥11.1b (down 5.8% from 3Q 2021). Net income: JP¥1.20b (down 5.9% from 3Q 2021). Profit margin: 11% (in line with 3Q 2021). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 4.0%. Over the next year, revenue is forecast to stay flat compared to a 7.3% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Feb 27
Daito Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Apr 14, 2022 Daito Pharmaceutical Co.,Ltd. announced that they will report Q3, 2022 results on Apr 14, 2022 Reported Earnings • Jan 16
Second quarter 2022 earnings: EPS exceeds analyst expectations Second quarter 2022 results: EPS: JP¥69.11 (down from JP¥80.36 in 2Q 2021). Revenue: JP¥10.7b (down 13% from 2Q 2021). Net income: JP¥952.0m (down 14% from 2Q 2021). Profit margin: 8.9% (in line with 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.0%. Earnings per share (EPS) surpassed analyst estimates by 4.0%. Over the next year, revenue is expected to shrink by 2.5% compared to a 7.1% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Nov 22
Upcoming dividend of JP¥25.00 per share Eligible shareholders must have bought the stock before 29 November 2021. Payment date: 01 February 2022. Trailing yield: 1.7%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.3%). Price Target Changed • Oct 16
Price target decreased to JP¥5,100 Down from JP¥5,600, the current price target is provided by 1 analyst. New target price is 54% above last closing price of JP¥3,310. Stock is down 19% over the past year. Reported Earnings • Oct 14
First quarter 2022 earnings released: EPS JP¥133 (vs JP¥98.06 in 1Q 2021) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2022 results: Revenue: JP¥11.7b (down 14% from 1Q 2021). Net income: JP¥1.83b (up 38% from 1Q 2021). Profit margin: 16% (up from 9.6% in 1Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 15
Daito Pharmaceutical Co.,Ltd. announced that it expects to receive ¥13.351 million in funding from Daiwa Securities Co., Ltd., Investment Arm Daito Pharmaceutical Co.,Ltd. announced a private placement of 13,000 2nd stock acquisition rights at issue price of ¥1,027 per stock acquisition right for gross proceeds of ¥13,351,000 on September 13, 2021. The transaction will include participation from returning investor, Daiwa Securities Co., Ltd., Investment Arm. The rights can be exercisable to purchase common shares of the company at an exercise price of ¥3,655 per share. The company shall issue securities pursuant to third-party allotment method. The rights can be exercised from September 30, 2021 to September 30, 2024. The transaction will close on September 29, 2021. The transaction has been approved by the board of directors of the company. Reported Earnings • Jul 16
Full year 2021 earnings released: EPS JP¥311 (vs JP¥310 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: JP¥48.7b (up 8.3% from FY 2020). Net income: JP¥4.25b (up 7.7% from FY 2020). Profit margin: 8.7% (down from 8.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 22
Upcoming dividend of JP¥23.00 per share Eligible shareholders must have bought the stock before 28 May 2021. Payment date: 06 August 2021. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.0%). Lower than average of industry peers (2.3%). Reported Earnings • Apr 16
Third quarter 2021 earnings released The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: JP¥11.8b (up 6.1% from 3Q 2020). Net income: JP¥1.28b (up 3.0% from 3Q 2020). Profit margin: 11% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Feb 26
Daito Pharmaceutical Co.,Ltd. to Report Q3, 2021 Results on Apr 14, 2021 Daito Pharmaceutical Co.,Ltd. announced that they will report Q3, 2021 results on Apr 14, 2021 Is New 90 Day High Low • Feb 24
New 90-day low: JP¥3,485 The company is down 5.0% from its price of JP¥3,680 on 26 November 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Is New 90 Day High Low • Jan 19
New 90-day low: JP¥3,500 The company is down 14% from its price of JP¥4,060 on 21 October 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period. Analyst Estimate Surprise Post Earnings • Jan 19
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 0.4%. Earnings per share (EPS) also surpassed analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 6.8%, compared to a 4.7% growth forecast for the Pharmaceuticals industry in Japan. 
